On March 24, 2005, Heeres, Jan; de Jonge, Marc R.; Koymans, Lucien M. H.; Daeyaert, Frits F. D.; Vinkers, Maarten; Van Aken, Koen J. A.; Arnold, Edward; Das, Kalyan; Kilonda, Amuri; Hoornaert, Georges J.; Compernolle, Frans; Cegla, Marek; Azzam, Rasha A.; Andries, Koen; de Bethune, Marie-Pierre; Azijn, Hilde; Pauwels, Rudi; Lewi, Paul J.; Janssen, Paul A. J. published an article.Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one The title of the article was Design, Synthesis, and SAR of a Novel Pyrazinone Series with Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitory Activity. And the article contained the following:
A series of novel pyrazinones designed as non-nucleoside reverse transcriptase inhibitors (NNRTIs) was synthesized and their anti-HIV structure-activity relationship (SAR) was studied. Optimization of activity was guided by mol. modeling, which in turn was based on x-ray structures of HIV-1 reverse transcriptase-bound 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile (dapivirine). An example compound thus prepared and studied was 3-[(4-chlorophenyl)amino]-5-(2,4-dimethylphenoxy)-1-methyl-2(1H)-pyrazinone (I). The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one
The Article related to design synthesis structure activity pyrazinone nonnucleoside hiv reverse transcriptase, mol modeling phenylamino phenoxy pyrazinone hiv reverse transcriptase dapivirine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one